

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 31/40, 31/445	A1	(11) International Publication Number: WO 97/44030 (43) International Publication Date: 27 November 1997 (27.11.97)
(21) International Application Number: PCT/IB97/00688 (22) International Filing Date: 15 May 1997 (15.05.97) (30) Priority Data: 60/017,889 17 May 1996 (17.05.96) US (71) Applicant (for all designated States except US): ANORMED INC. [CA/CA]; No 100 20353-64th Avenue, Langley, British Columbia V2Y 1N5 (CA). (72) Inventors; and (75) Inventors/Applicants (for US only): BADGER, Alison, Mary [US/US]; 56 Parkridge Drive, Bryn Mawr, PA 19010 (US). GLEASON, John, Gerald [CA/US]; 8 Herton Hill Drive, Downingtown, PA 19335 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: USE OF SUBSTITUTED AZASPIRANE IN THE TREATMENT OF ASTHMA (57) Abstract Invented is a method of treating asthma, in mammals, including humans, which comprises administering to such human an effective amount of a substituted azaspirane.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

USE OF SUBSTITUTED AZASPIRANE IN THE TREATMENT OF ASTHMA

METHODS

This invention relates to a method of treating asthma, in mammals, including humans, which comprises administering to such human an effective amount of a substituted azaspirane.

Badger *et al* US Patent No. 4,963,557 (Badger I) discloses compounds of the Formula I



I

wherein:

n is 3-7;

m is 1 or 2;

5 R¹ and R² are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R¹ and R² when taken together is 5-10; or R¹ and R² together form a cyclic alkyl group having 3-7 carbon atoms;

10 R³ and R⁴ are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R³ and R⁴ are joined together with the nitrogen atom to form a heterocyclic group having 5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof.

Badger I discloses compounds of Formula I as a class of novel compounds which induce an immunomodulatory effect which is characterised by the stimulation of suppressor cell activity. Particular disease states treatable with the compounds of Formula I, as disclosed in Badger I, are: rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, acute transplantation/graft rejection, myasthenia gravis, progressive systemic sclerosis, multiple myeloma, atopic dermatitis, hyperimmunoglobulin E, hepatitis B antigen negative chronic active hepatitis, Hashimoto's thyroiditis, Familial Mediterranean fever, Grave's disease, autoimmune hemolytic anaemia, primary biliary cirrhosis and inflammatory bowel disease.

15
20

International Application No. PCT/US91/06778, having the International Publication No. WO 92/04899 and an International Publication Date of 2 April 1992,

discloses compounds of the above Formula I as being useful in treating a disease state which is exacerbated or caused by excessive glucose levels.


International Application No. PCT/US92/01283, having the International
5 Publication No. WO 92/14462 and an International Publication Date of 3 September 1992 (Badger II), discloses the compounds of the above Formula I as being useful in the inhibition of cytokines. Preferred disease states treatable with the compounds of Formula I, as disclosed in Badger II, are: increased bone resorption (including osteoporosis and Paget's disease), endotoxic shock, cachexia secondary to acquired
10 immune deficiency syndrome (AIDS), AIDS and malaria.

US Patent No. 5,482,959 discloses compounds of the above Formula I as being useful in delaying AIDS in HIV infected individuals.

15 International Application No. PCT/US94/08275, having the International Publication No. WO 95/03041 and an International Publication Date of 2 February 1995, International Application No. PCT/US94/08274, having the International Publication No. WO 95/03049 and an International Publication Date of 2 February 1995, and International Application No. PCT/US94/08276, having the International Publication
20 No. WO 95/03042 and an International Publication Date of 2 February 1995, disclose the compounds of the above Formula I as being useful in various mechanisms of HIV inhibition.

None of the above references disclose the compounds of Formula I as being useful in treatment of asthma.

This invention relates to a method of treating asthma, in mammals, including humans, which comprises administering to a subject in need thereof an effective amount of a compound of the Formula I



wherein:

n is 3-7;

m is 1 or 2;


R^1 and R^2 are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R^1 and R^2 when taken together is 5-10; or R^1 and R^2 together form a cyclic alkyl group having 3-7 carbon atoms;

R^3 and R^4 are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R^3 and R^4 are joined together with the nitrogen atom to form a heterocyclic group having 5-8 atoms;

or a pharmaceutically acceptable salt or hydrate or solvate thereof.

In the alternative this invention relates to the use of a compound of

Formula I



wherein:

n is 3-7;

m is 1 or 2;

R^1 and R^2 are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R^1 and R^2 when taken together is 5-10; or R^1 and R^2 together form a cyclic alkyl group having 3-7 carbon atoms;

R^3 and R^4 are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R^3 and R^4 are joined together with the nitrogen atom to form a heterocyclic group having 5-8 atoms;

or a pharmaceutically acceptable salt or hydrate or solvate thereof;

in the manufacture of a medicament for use in treating asthma in mammals, including humans.

The preparation of compounds of Formula I and pharmaceutically acceptable salts, hydrates and solvates and formulations thereof is disclosed in US Patent No. 4,963,557, the entire disclosure of which is hereby incorporated by reference.

A preferred compound used in the novel method is the dimaleate salt of a compound of Formula I where R^1 and R^2 are propyl, R^3 and R^4 are methyl, m is 1 and n is 3 which is N,N-dimethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine dimaleate.

5

A particularly preferred compound used in the novel method is the dimaleate salt of a compound of Formula I where R^1 and R^2 are propyl, R^3 and R^4 are ethyl, m is 1 and n is 3 which is N,N-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine dimaleate.

10

A particularly preferred compound used in the novel method is the dimaleate salt of a compound of Formula I where R^1 and R^2 are propyl, R^3 and R^4 are joined together with the nitrogen to form a piperidine ring, m is 1 and n is 3 which is 8,8-dipropyl-2-azaspiro[4.5]decane-2-piperidinopropyl dimaleate.

15

The above dimaleate salts can be prepared by dissolving the base in an appropriate organic solvent, such as de-oxygenated ethyl acetate, with subsequent addition of two or more equivalents of maleic acid.

20

By the term "treating" as used herein is meant prophylactic or therapeutic therapy.

The invention discloses compounds of Formula I and pharmaceutically acceptable salts or hydrates or solvates thereof as being useful for treating asthma in mammals, including humans.

5 The compounds of Formula I are tested for their ability to treat asthma in the assay described in Anderson, Br. J. Pharmac. (1983), 78, 67-74.

 This invention relates to a method of treating asthma which comprises administering to a subject in need thereof an effective amount of a compound of
10 Formula I or a pharmaceutically acceptable salt or hydrate or solvate thereof. The invention also relates to the use of a compound of Formula I or a pharmaceutically acceptable salt or hydrate or solvate thereof in the manufacture of a medicament for use in treating asthma. A compound of Formula I or a pharmaceutically acceptable salt or hydrate or solvate thereof can be administered to such subject in a conventional dosage
15 form prepared by combining a compound of Formula I or a pharmaceutically acceptable salt or hydrate or solvate thereof, with a conventional pharmaceutically acceptable carrier or diluent according to known techniques, such as those described in Badger I, US Patent No. 4,963,557.

20 It will be recognised by one skilled in the art that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. A compound of Formula I ("Active Ingredient") or a pharmaceutically acceptable salt or hydrate or solvate thereof is administered to a subject in need of

treatment for asthma in an amount sufficient to prevent or alleviate the asthmatic condition.

5 The route of administration of the Formula I compound is not critical but is usually oral or parenteral, preferably oral.

10 The term parenteral as used herein includes intravenous, intramuscular, subcutaneous, intranasal, intrarectal, transdermal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. The daily parenteral dosage regimen will preferably be from about 0.01mg/kg to about 10mg/kg of total body weight, most preferably from 0.1mg/kg to about 1mg/kg. Preferably, each parenteral dosage unit will contain the active ingredient in an amount of from about 0.1mg to about 100mg.

15 The compounds of Formula I which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.

20 A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent.

A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose, and cellulose.

5 A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension
10 then filled into a soft gelatin capsule.

The daily oral dosage regimen will preferably be from about 0.01mg/kg to about 10mg/kg of total body weight. Preferably each oral dosage unit will contain the active ingredient in an amount of from about 0.1mg to about 100mg.

15

While it is possible for an active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation.

It will be recognised by one of skill in the art that the optimal quantity
20 and spacing of individual dosages of a compound of Formula I or a pharmaceutically acceptable salt or hydrate or solvate thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the

optimal course of treatment, *ie*, the number of doses of a compound of Formula I or a pharmaceutically acceptable salt or hydrate or solvate thereof given *per* day and duration of therapy, can be ascertained by those skilled in the art using conventional course of treatment determination tests.

5

The method of this invention of treating asthma in mammals, including humans, comprises administering to a subject in need of such treatment an effective amount of a pharmaceutically active compound of the present invention.

10

The invention also provides for the use of a compound of Formula I in the manufacture of a medicament for use in treating asthma in mammals, including humans.

15

The invention also provides for a pharmaceutical composition for use in treating asthma in mammals, including humans which comprises a compound of Formula I and a pharmaceutically acceptable carrier.

20

The invention also provides for a process for preparing a pharmaceutical composition containing a pharmaceutically acceptable carrier or diluent and a compound of Formula I which comprises bringing the compound of Formula I into association with the pharmaceutically acceptable carrier or diluent.

No unacceptable toxicological effects are expected when compounds of the invention are administered in accordance with the present invention.

In addition, the compounds of the present invention can be co-administered with further active ingredients known to treat asthma.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilise the present invention to its fullest extent. The following examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.

EXAMPLE 1

10

CAPSULE COMPOSITION

An oral dosage form for administering Formula I compounds is produced by filling a standard two-piece hard gelatin capsule with the ingredients in the proportions shown in Table I, below.

15

TABLE 1

	<u>Ingredients</u>	<u>Amounts</u>
	N,N-diethyl-8,8-dipropyl-2-azaspiro[4.5]-	
	decane-2-propanamine dimaleate	25mg
20	Lactose	55mg
	Talc	16mg
	Magnesium Stearate	4mg

EXAMPLE 2**INJECTABLE PARENTERAL COMPOSITION**

An injectable form for administering Formula I compounds is produced
5 by stirring 1.5% by weight of N,N-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-
propanamine dimaleate in 10% by volume propylene glycol in water.

EXAMPLE 3**TABLET COMPOSITION**

10

The sucrose, calcium sulphate dihydrate and Formula I compound shown
in Table II below, are mixed and granulated in the proportions shown with a 10% gelatin
solution. The wet granules are screened, dried, mixed with the starch, talc and stearic
acid, screened and compressed into a tablet.

15

TABLE II

	<u>Ingredients</u>	<u>Amounts</u>
	N,N-diethyl-8,8-dipropyl-2-azaspiro[4.5]	
	decane-2-propanamine dimaleate	20mg
20	Calcium sulphate dihydrate	30mg
	Sucrose	4mg
	Starch	2mg
	Talc	1mg
	Stearic acid	0.5mg

EXAMPLE 4**INHIBITION OF ANTIGEN-INDUCED AIRWAY EOSINOPHIL INFILUX**


5 The inhibition of antigen-induced airway eosinophil influx was demonstrated for the following compound:

 N,N-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine dihydrochloride (Compound A). The results are shown in Figure 1 (Compound A).

10 While the above descriptions and examples fully describe the invention and the preferred embodiments thereof, it is understood that the invention is not limited to the particular disclosed embodiments coming within the scope of the following claims.

CLAIMS

1. A method of treating asthma, in mammals, including humans, which comprises administering to such human an effective amount of a compound of formula



wherein:

n is 3-7;

10 m is 1 or 2;

R¹ and R² are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R¹ and R² when taken together is 5-10; or R¹ and R² together form a cyclic alkyl group having 3-7 carbon atoms;

15 R³ and R⁴ are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R³ and R⁴ are joined together with the nitrogen atom to form a heterocyclic group having 5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof.

20 2. The method of claim 1 wherein the compound is N,N-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine; or a pharmaceutically acceptable salt, hydrate or solvate thereof.


3. The method of claim 1 wherein the compound is administered orally.

4. The method of claim 3 wherein from about 0.01mg/kg to about 10mg/kg of compound is administered *per* day.

5. The method of claim 1 wherein the compound is administered parenterally.

6. The method of claim 5 wherein from about 0.01mg/kg to about 10mg/kg of compound is administered *per* day.

7. The use of a compound of formula I



wherein:

n is 3-7;

m is 1 or 2;

R¹ and R² are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R¹ and R² when taken together is 5-10; or R¹ and R² together form a cyclic alkyl group having 3-7 carbon atoms;

R³ and R⁴ are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R³ and R⁴ are joined together with the nitrogen atom to form a heterocyclic group having 5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof in the manufacture of a medicament for use in treating asthma in mammals.

8. The use according to claim 7 wherein the compound is N,N-diethyl-8,8-dipropyl-2-azaspiro[4.5]decane-2-propanamine or a pharmaceutically acceptable salt, hydrate or solvate thereof.


5 9. The use according to claim 7 or 8 wherein the compound is administered orally.

10. The use according to claim 7 or 8 wherein the compound is administered parenterally.

10

11. The use according to claim 9 or 10 wherein from about 0.01mg/kg to about 10mg/kg of the compound is administered *per* day.

1/1

Figure 1

INTERNATIONAL SEARCH REPORT

Intern. Application No
PCT/IB 97/00688

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/40 A61K31/445

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 92 14462 A (SMITHKLINE BEECHAM CORP) 3 September 1992 cited in the application see page 4, line 1 - page 5, line 18; claim 1	1-11
Y	--- RESPIRATORY MEDICINE, vol. 89, no. SUPPL. A, September 1995, UK, pages 3-18, XP002037680 FULLER ET AL: "FLUTICSONE PROPRIONATE - AN UPDATE ON PRECLINICAL AND CLINICAL EXPERIENCE" see abstract --- -/-	1-11

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

13 August 1997

Date of mailing of the international search report

11 09. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+ 31-70) 340-3016

Authorized officer

Herrera, S

INTERNATIONAL SEARCH REPORT

Inter. nal Application No

PCT/IB 97/00688

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 153, no. 2, February 1996, USA, pages 551-556, XP002037681 BENTLEY ET AL: "PREDNISOLONE TREATMENT IN ASTHMA. REDUCTION IN THE NUMBERS OF EOSINOPHILS, T-CELLS, TRYPTASE-ONLY POSITIVE MAST CELLS, AND MODULATION OF IL-4, IL-5, AND INTERFERON-GAMMA CYTOKINE GENE EXPRESSION WITHIN THE BRONCHIAL MUCOSA." see abstract -----	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/IB 97/00688

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9214462 A	03-09-92	AU 657745 B	23-03-95
		AU 1463392 A	15-09-92
		CA 2104214 A	20-08-92
		EP 0572537 A	08-12-93
		JP 6505483 T	23-06-94
		US 5602166 A	11-02-97
